NewslettersDermal Cell NewsImmune Regulation News Aslan Sells Japanese Rights to Would-Be Dupixent Rival for $12M By Laurisa Dohm - June 26, 2023 0 Zenyaku Kogyo is lining up a challenge to Sanofi and Regeneron’s blockbuster Dupixent in Japan, paying Aslan Pharmaceuticals $12 million upfront for local rights to a midphase eczema drug candidate. [Fierce Biotech] Press Release